Nguyen AnhCo's Form 4 filing
Atara Biotherapeutics, Inc.ATRA · filed Aug 26, 2026
- Accession no.
- 0000905148-26-003960
- Filed
- Aug 26, 2026, 7:45 PM ET
- Trade date
- Aug 17, 2026
- Filing delay
- 9 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $40.9K. It was filed 9 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Nguyen AnhCoCIK 0001977970 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | Common Stock | SSaleDisposed | −5,062 | $8.08F2 | −$40,882.74 | 132,775 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2026, on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
Referenced by the price of 1 transaction in Table I.
Remarks
Exhibit List: Exhibit 24 - Power of Attorney